Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-07-18
2006-07-18
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S851000, C514S051000, C514S012200, C514S277000, C536S025600, C536S026100, C424S045000, C424S427000, C623S041000, C606S107000
Reexamination Certificate
active
07078391
ABSTRACT:
The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The pharmaceutical formulation useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compounds, or hydrolysis-resistant mononucleoside triphosphates.
REFERENCES:
patent: 6040297 (2000-03-01), De Flora et al.
patent: 6258374 (2001-07-01), Freiss et al.
patent: 6277855 (2001-08-01), Yerxa
patent: 6319908 (2001-11-01), Yerxa et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: 6348589 (2002-02-01), Pendergast et al.
patent: 6458946 (2002-10-01), Maeda et al.
patent: 6548658 (2003-04-01), Yerxa
patent: 6555675 (2003-04-01), Rideout et al.
patent: 6596725 (2003-07-01), Peterson et al.
patent: 6673779 (2004-01-01), Jacobus et al.
patent: 6696425 (2004-02-01), Yerxa et al.
patent: 2002/0156269 (2002-10-01), Maeda et al.
patent: 1 191 032 (2002-03-01), None
patent: 1 043 329 (2002-08-01), None
patent: WO 98/34593 (1998-08-01), None
patent: WO 98/34942 (1998-08-01), None
patent: WO 00/30629 (2000-06-01), None
patent: WO 01/87913 (2001-11-01), None
Maminishkis et al. IOVS, 43(11), 3555-3566, 2002.
International Preliminary Examination Report, Oct. 1, 2004, PCT.
Blaug, et al., “P2Y2 receptor agonists induce prolonged calcium, membrane voltage, conductance and fluid absorption increases in bovine RPE,”IOVS, 41(4):S136 (2000) XP001088187.
Burnstock, et al., “P2 purinergic receptors: Modulation of cell function and therapeutic potential,”Journal of Pharmacology and Experimental Therapeutics 295(3) 862-869 (2000) XP002208652.
Ferris, et al., “Oligomerization reactions of deoxyribonucleotides on montmorillonite clay: the effect of mononucleotide structure on phosphodiester bond formation,”Origins Life Evol. Biosphere, 19(6):609-619 (1989) XP001085277.
Maminishkis, et al., “Purinoceptor agonists increase fluid clearance out of subretinal space (SRS) blebs in vivo,”IOVS, 41(4):S136 (2000) XP001083820.
Maminishkis, et al., “The P2Y2Receptor Agonist INS37217 Stimulates RPE Fluid Transport In Vitro and Retinal Reattachment in Rat,”IOVS, 43(11): 3555-3566 (2002).
Meyer, et al., “Effect of INS37217, a P2Y2Receptor Agonist, on Experimental Retinal Detachment and Electroretinogram in Adult Rabbits,”IOVS, 43(11): 3567-3574 (2002).
Nour, et al., “P2Y2Receptor Agonist INS37217 Enhances Functional Recovery After Detachment Caused by Subretinal Injection in Normal andrdsMice,” IOVS, 44(10): 4505-4514 (2003).
Peterson, et al., “Extracellular ATP activates calcium signaling, ion, and fluid transport in retinal pigment epithelium,”Journal of Neuroscience, 17:(7)2324-2337 (1997) XP001087693.
Sillero, et al., (2′,3′-Dideoxynucleoside triphosphates (ddNTP) and di-2',3'-dideoxynucleoside tetraphosphates (ddNp4ddN) behave differently to the corresponding NTP and NP4N counterparts as substrates of firefly luciferase and dinucleoside tetraphosphatase and phosphodiesterases,Biochemica et Biophysica Acta 1334(2-3):191-199 (1997) XP002208651.
Takahasi, et al., “Effect on Nucleotide P2Y2Receptor Agonists on Outward Active Transport of Fluorescein Across Normal Blood-retina Barrier in Rabbit,”Experimental Eye Research78:103-108, (2004).
Theoclitou, et al., “Characterization of stress protein LysU. Enzyme synthesis of diadenosine 5′,5″-P1,P4-tetraphosphate (Ap4A) analogs by LysU,”J. Chem. Soc., Perkins Trans. 1(16):2009-2019 (1996) XP00108769.
Williams, M., “P2 Receptros as drug discovery targets,”Am. Chem. Soc.220th, Medi-185 (2000) XP001085299.
Peterson Ward M.
Yerxa Benjamin R.
Howery LLP
Inspire Pharmaceuticals Inc.
Jiang Shaojia Anna
Khare Devesh
Kung Viola T.
LandOfFree
Method of treating edematous retinal disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating edematous retinal disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating edematous retinal disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3565265